Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
Real-time Euronext Paris  -  09:45:28 2023-02-02 am EST
2.100 EUR   -0.47%
01/09Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
AQ
01/06Transgene Gets French Nod To Launch Early-stage Trial For Non-small Cell Lung Cancer Drug
MT
01/06Transgene Receives Approval to Start a Phase I Trial of TG6050
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
1.98(c) 1.962(c) 1.972(c) 2.11(c) 2.1 Last
12 590 20 149 22 894 194 150 72 271 Volume
+0.51% -0.91% +0.51% +7.00% -0.47% Change
More quotes
Estimated financial data (e)
Sales 2022 12,5 M 13,6 M 13,6 M
Net income 2022 -31,8 M -34,7 M -34,7 M
Net cash position 2022 39,1 M 42,7 M 42,7 M
P/E ratio 2022 -6,59x
Yield 2022 -
Sales 2023 17,1 M 18,6 M 18,6 M
Net income 2023 -31,6 M -34,5 M -34,5 M
Net cash position 2023 39,4 M 43,0 M 43,0 M
P/E ratio 2023 -6,49x
Yield 2023 -
Capitalization 210 M 229 M 229 M
EV / Sales 2022 13,7x
EV / Sales 2023 9,99x
Nbr of Employees 143
Free-Float 100%
More Financials
Company
Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene's four lead clinical-stage programs are: TG4001 for HPV positive... 
Read more
More about the company
Ratings of Transgene
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about TRANSGENE
01/09Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Onc..
AQ
01/06Transgene Gets French Nod To Launch Early-stage Trial For Non-small Cell Lung Cancer Dr..
MT
01/06Transgene Receives Approval to Start a Phase I Trial of TG6050
CI
2022European Midday Briefing: Pre-Fed Caution Dominates Despite Sof..
DJ
2022Transgene : Inside Information / Other news releases
PU
20224D Molecular Therapeutics Says Interim Data From Phase 1/2 Trial of Gene Therapy for Lu..
MT
2022Transgene Discloses Positive Interim Analysis Results of Phase 2 Trial of TG4001, Avelu..
MT
2022Transcript : Transgene SA - Special Call
CI
2022Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG40..
CI
20224D Molecular Therapeutics Shares Sharply Higher Amid Heavy Volume
MT
2022Transcript : Transgene SA - Special Call
CI
2022Transgene : Inside Information / Other news releases
PU
2022Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Vir..
CI
2022Transcript : Transgene SA, H1 2022 Earnings Call, Sep 07, 2022
CI
2022Transgene SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
More news
News in other languages on TRANSGENE
02/01Transgene : présente des résultats encourageants pour son vaccin anticancer pe..
01/26bioMérieux : Dynastie Mérieux : la santé comme métier
01/10Transgene : Invest Securities confirme son conseil
01/06Transgene : le titre avance, un essai autorisé en France
01/06Transgene : reçoit l’autorisation de lancer un essai de Phase I avec son virus..
More news
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,11 €
Average target price 3,95 €
Spread / Average Target 87,2%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chief Executive Officer & Director
Jean-Philippe Del Chief Financial Officer
Alessandro Riva Non-Executive Chairman
Eric Quéméneur Chief Scientific Officer & Executive VP
Maud Brandely VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE27.26%229
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.15.90%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436